As we begin to understand the cause of disease in more detail, we begin to generate increasingly complex diagnostics and treatment methods. Because radiology and nuclear medicine technologies play an important role in these methods, we are committed to their advancement through medical device and diagnostic development.

Chiltern has a team of medical professionals who have a history of identifying solutions to obtain better clinical outcomes and capitalize on diagnostics growth opportunities — adding support and value to your project. Working as a cross-functional group, the team collaborates with you to provide advice from medical, operational, regulatory and cost-efficiency perspectives. The relationships they foster with industry leaders and key professionals allow them to provide deeper insights and strategic guidance, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals.

In addition to in vitro diagnostics studies, Chiltern supports complex diagnostics studies, primarily for premarket submission. Our experience is global, with studies supported in the Asia-Pacific, South Africa, North America, Latin America and Western and Eastern Europe regions.

Over the last five years, Chiltern has conducted nine radiology and nuclear medicine studies.

Radiology and Nuclear Medicine

Total Studies

Top Radiology & Nuclear Medicine Indications From the Past Five Years

  • Aging
  • Alzheimer’s disease
  • Breast cancer
  • Coronary artery disease
  • Depression
  • Endocrinology disorders
  • Influenza
  • Liver lesions
  • Progressive cognitive decline
  • Traumatic brain injury

Let us help you reach your program’s goals with a comprehensive range of collaborative services: